Short-term risk of psychiatric adverse events following COVID-19 vaccination: nationwide self-controlled case series study.

Short-term risk of psychiatric adverse events following COVID-19 vaccination: nationwide self-controlled case series study.

Publication date: Sep 22, 2025

To date, little is known about the evidence of a potential risk of psychiatric adverse events following COVID-19 vaccination in large populations with adequate study design. To investigate whether COVID-19 vaccination is associated with increased risk of psychiatric adverse events. We used South Korea’s linkage database to obtain registry data and claims data from 2019 to 2021, and conducted a population-based self-controlled case series study including 11 751 806 individuals. Primary outcomes included anxiety/nervousness, mood disorders, perceptual disturbances/psychoses, aggression/behavioural disturbances, cognitive impairments and sleep disorders within 21 days of COVID-19 vaccination. Secondary outcomes were the stratified primary outcomes according to each individual’s psychiatric history. Conditional Poisson regression was used to estimate incidence rate ratios (IRR) and 95% confidence intervals. COVID-19 vaccination did not increase the rate of anxiety and nervousness (adjusted IRR 0. 95, 95% CI 0. 95-0. 96), mood disorders (adjusted IRR 0. 75, 95% CI 0. 75-0. 76), perceptual disturbances and psychoses (adjusted IRR 0. 72, 95% CI 0. 70-0. 74), aggression and behavioural disturbances (adjusted IRR 0. 93, 95% CI 0. 89-0. 97), cognitive impairment (adjusted IRR 0. 68, 95% CI 0. 67-0. 69) or sleep disorders (adjusted IRR 0. 90, 95% CI 0. 89-0. 91). Secondary outcomes were consistent with the primary outcome, although the adjusted IRRs for anxiety and nervousness (adjusted IRR 1. 17, 95% CI 1. 15-1. 18) and sleep disorders (adjusted IRR 1. 07, 95% CI 1. 06-1. 09) were statistically significant in individuals with no history of psychiatric disorders. Sensitivity analyses showed consistent results with our main findings. Our findings provide short-term safety profiles for COVID-19 vaccines regarding psychiatric adverse events. Continuous monitoring of anxiety/nervousness or sleep disorders after COVID-19 vaccination is required regardless of history of psychiatric comorbidities.

Open Access PDF

Concepts Keywords
Korea COVID-19 vaccine
Nervousness psychiatric adverse events
Vaccination self-controlled case series

Semantics

Type Source Name
disease MESH COVID-19
disease MESH anxiety
disease MESH mood disorders
disease MESH psychoses
disease MESH cognitive impairments
disease MESH sleep disorders
disease IDO history
disease MESH psychiatric disorders
pathway REACTOME Reproduction
disease MESH infection transmission
disease MESH myocarditis
disease MESH pericarditis
disease MESH thrombosis
disease MESH syndrome
disease MESH confusion
disease MESH mania
disease MESH depression
disease MESH insomnia
disease MESH hallucinations
disease MESH infection
drug DRUGBANK Timonacic
disease MESH death
disease MESH causality
drug DRUGBANK Coenzyme M
disease MESH inflammation
disease MESH seizures
disease MESH panic attacks
disease MESH viral infection
disease IDO host
disease MESH psychological distress
disease MESH uncertainty
disease MESH anxiety disorder
disease IDO susceptibility
disease MESH hypersomnolence
disease MESH tachycardia
disease MESH hyperventilation
disease MESH chest pain
disease MESH hypotension
disease MESH pallor
disease MESH syncope
disease IDO site
drug DRUGBANK (S)-Des-Me-Ampa
pathway REACTOME Immune System
disease MESH social anxiety disorder

Original Article

(Visited 5 times, 1 visits today)

Leave a Comment

Your email address will not be published. Required fields are marked *